Whenever intravenous idarubicin hydrochloride cannot be employed e.g. for medical, psychological or social reasons, oral idarubicin can be used for remission induction in patients with previously untreated, relapsed or refractory acute non-lymphocytic leukaemia. Zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents. As a single agent in the treatment of advanced breast cancer after failure of front line chemotherapy not including anthracyclines.
Acute non-lymphocytic leukaemia (ANLL). Whenever intravenous idarubicin hydrochloride cannot be employed e.g. for medical, psychological or social reasons, oral idarubicin can be used for remission induction in patients with previously untreated, relapsed or refractory acute non-lymphocytic leukaemia. Zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents. As a single agent in the treatment of advanced breast cancer after failure of front line chemotherapy not including anthracyclines.
Adults For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients. For second line treatment of relapsed acute lymphoblastic leukaemia (ALL). Paediatric population For first line treatment of acute myeloid-leukaemia (AML), in combination with cytarabine, for remission induction. For second line treatment of relapsed acute lymphoblastic leukaemia (ALL). Zavedos may be used in combination chemotherapy regimens involving other cytotoxic agents (see section 4.2).
Cempra has announced the publication of positive results from its pivotal Phase III clinical trial of Solitaire (solithromycin oral capsules)...